ارزیابی پنومونی بینابینی ناشی از استاتین در بیماران تحت درمان با هیپرلیپیدمی با استفاده از ادعای بیمه در بیمه درمانی ژاپن

We clarified the incidence (0.009% and 0.6% in patients without and with lung-related disease history that were known to the risk factors inducing IP, respectively) and risk factors for statin-induced IP (elderly females without lung-related disease history; atorvastatin administration in those with lung-related disease history). Physicians and pharmacists should pay close attention to female patients starting atorvastatin, especially those with past histories of lung-related diseases that were known to the risk factors for IP.